Novartis India Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Attractively valued vs sector (P/E 38.8x vs industry 50.2x)
- Virtually debt-free
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
NOVARTIND · as of Dec 2025
| Category | Jul 2026 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|
| Promoters | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% |
| FII | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% |
| DII | 0.53% | 0.52% | 0.52% | 0.52% | 0.52% | 0.53% |
| Public | 28.61% | 28.60% | 28.61% | 28.60% | 28.61% | 28.60% |
Latest News
All newsNovartis India to buy Pfizer's Minipress for ₹1,250 crore
*Novartis India to buy Pfizer's Minipress for ₹1,250 crore.* The acquisition includes trademarks and rights to Minipress, a hypertension drug. This strategic move strengthens Novartis India's portfolio in cardiovascular therapies. The deal value of **₹1,250 crore** marks one of the larger pharma asset purchases in India recently. 📊 *STOCKS:* $NOVARTISIND | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Acquisition
Novartis India jumps 4% on ₹1,250 cr Pfizer trademarks deal
*Novartis India jumps 4% on ₹1,250 cr Pfizer trademarks deal.* The company acquired Pfizer’s consumer health trademarks in India for **₹1,250 crore**, boosting its OTC portfolio. The acquisition strengthens Novartis’s position in the fast-growing wellness segment. It marks a strategic expansion in the domestic pharma space. 📊 *STOCKS:* NOVARTISIND | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Acquisition
ChrysCapital acquires controlling stake in Novartis India
*ChrysCapital acquires controlling stake in Novartis India; Vikas Gupta named MD & CEO.* The deal marks a major shift in ownership, with ChrysCapital now in control. **Vikas Gupta** has been appointed as the new MD & CEO, signaling strategic leadership change. This acquisition reflects strong investor confidence in the Indian pharma sector. 📊 *STOCKS:* $NOVARTISINDIA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Acquisition
ChrysCapital acquires Novartis India, appoints new CEO
*ChrysCapital has completed its acquisition of Novartis India.* The PE firm has appointed Vikas Gupta, former Alkem executive, as CEO. This marks a significant leadership and ownership shift for the company. **No financial terms were disclosed**. 📊 *STOCKS:* $NOVARTISINDIA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Acquisition
ChrysCapital buys controlling stake in Novartis India
*ChrysCapital acquires controlling stake in Novartis India and appoints a new CEO.* This marks a major shift in ownership and leadership. The deal underscores strong investor interest in Indian pharma assets. **Controlling stake acquisition** could lead to strategic realignment. 📊 *STOCKS:* $NOVARTIND | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #M&A
Novartis India reports lower net profit, plans stake sale.
*Novartis India reports lower net profit, plans stake sale.* Q4 and FY26 earnings showed a decline in net profit, missing analyst expectations. The company announced a **stake sale to a consortium**, signaling strategic restructuring. Deal size and terms remain undisclosed. 📊 *STOCKS:* NOVARTISIND | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Earnings
Alembic Pharma gets USFDA tentative nod for Binimetinib tablets
*Alembic Pharma gets USFDA tentative nod for Binimetinib tablets* — Alembic Pharmaceuticals has received tentative approval from the USFDA for its Binimetinib Tablets, 45 mg. The drug is a generic version of Novartis’ Mektovi tablets, used for treating melanoma. Tentative approval means the product can launch upon patent expiry or final regulatory clearance. This positions Alembic to enter the US market early and gain revenue momentum. 📊 *STOCKS:* APLLTD | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA
NALCO partners EGA for Odisha smelter expansion
*NALCO partners EGA for Odisha smelter expansion*. The collaboration aims to enhance smelter capacity with an investment of **$1.2 billion**. The project will boost aluminum production and strengthen NALCO’s position in the global market. EGA brings technical expertise while NALCO provides raw material access. 📊 *STOCKS:* $NALCO | 🏢 *SECTOR:* Metals | #MEDIUMIMPACT #Expansion
Novartis India expands via MNC tie-ups, brand deals
*Novartis India expands via MNC tie-ups, brand deals.* The ChrysCapital-controlled firm is broadening its product portfolio through strategic collaborations with multinational companies and new brand partnerships. This move aims to strengthen its position in the competitive domestic pharma market. Expansion efforts are focused on high-growth therapeutic segments. 📊 *STOCKS:* $NOVARTIND | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma
Novartis India plans therapy-focused acquisition and Tier 2-3 expansion
*Novartis India plans therapy-aligned acquisition and Tier 2-3 market expansion.* The move aims to strengthen its specialty care portfolio and deepen regional presence. Strategic acquisition could exceed **₹500 crore**, boosting long-term growth. Expansion targets higher patient reach in underserved markets. 📊 *STOCKS:* $NOVARTIS | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Acquisition